Medical XpressNovel Prostate Cancer Treatment Can Reduce Risk of Disease Progression by Half, Clinical Trial Shows

The phase 3 TALAPRO-3 trial randomized 599 men with metastatic castration-sensitive prostate cancer harboring HRR gene alterations, including BRCA1/2, present in approximately 25–30% of this population, to talazoparib plus enzalutamide or enzalutamide alone. The combination targets both androgen receptor signaling and DNA damage repair simultaneously, building on TALAPRO-2 data in castration-resistant disease.

Clinical Considerations

• Combination therapy reduced risk of radiographic progression or death by 52% vs. enzalutamide alone; 3-year rPFS 77% vs. 56% across the HRR-altered population
• Benefit extended across BRCA and non-BRCA HRR mutations, broadening the potentially eligible population beyond BRCA1/2-specific selection
• Patient-reported outcomes showed no meaningful deterioration in most quality-of-life measures versus enzalutamide alone, which is clinically relevant given the castration-sensitive treatment context
• Overall survival data were not reported; durability of the rPFS signal and its translation to OS benefit remain to be established

Practice Applications

• Integrate routine HRR genetic testing into workup for metastatic castration-sensitive prostate cancer; TALAPRO-3 reinforces testing as a prerequisite for treatment selection, not an optional add-on
• Recognize that talazoparib plus enzalutamide currently holds FDA approval only in castration-resistant disease; the castration-sensitive indication remains investigational pending regulatory submission
• Monitor for FDA sNDA filing and label expansion into the castration-sensitive setting as the next regulatory milestone
• Anticipate hematologic toxicity management protocols will be relevant if the combination moves into earlier-line use, consistent with known PARP inhibitor class effects